IBDEI1EB ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25032,1,5,0)
 ;;=5^RELATIONAL PROBLEM
 ;;^UTILITY(U,$J,358.3,25032,2)
 ;;=^303721
 ;;^UTILITY(U,$J,358.3,25033,0)
 ;;=V65.42^^163^1619^39
 ;;^UTILITY(U,$J,358.3,25033,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25033,1,2,0)
 ;;=2^V65.42
 ;;^UTILITY(U,$J,358.3,25033,1,5,0)
 ;;=5^SUBSTANCE ABUSE COUNSELING
 ;;^UTILITY(U,$J,358.3,25033,2)
 ;;=^303467
 ;;^UTILITY(U,$J,358.3,25034,0)
 ;;=V62.0^^163^1619^40
 ;;^UTILITY(U,$J,358.3,25034,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25034,1,2,0)
 ;;=2^V62.0
 ;;^UTILITY(U,$J,358.3,25034,1,5,0)
 ;;=5^UNEMPLOYMENT
 ;;^UTILITY(U,$J,358.3,25034,2)
 ;;=^123545
 ;;^UTILITY(U,$J,358.3,25035,0)
 ;;=V65.49^^163^1619^30
 ;;^UTILITY(U,$J,358.3,25035,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25035,1,2,0)
 ;;=2^V65.49
 ;;^UTILITY(U,$J,358.3,25035,1,5,0)
 ;;=5^OTHER SPECIFIED COUNSELING
 ;;^UTILITY(U,$J,358.3,25035,2)
 ;;=^303471
 ;;^UTILITY(U,$J,358.3,25036,0)
 ;;=V58.61^^163^1619^17
 ;;^UTILITY(U,$J,358.3,25036,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25036,1,2,0)
 ;;=2^V58.61
 ;;^UTILITY(U,$J,358.3,25036,1,5,0)
 ;;=5^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,25036,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,25037,0)
 ;;=V58.62^^163^1619^19
 ;;^UTILITY(U,$J,358.3,25037,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25037,1,2,0)
 ;;=2^V58.62
 ;;^UTILITY(U,$J,358.3,25037,1,5,0)
 ;;=5^L/T (CURRENT) USE ANTIBIOTIC
 ;;^UTILITY(U,$J,358.3,25037,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,25038,0)
 ;;=V58.63^^163^1619^21
 ;;^UTILITY(U,$J,358.3,25038,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25038,1,2,0)
 ;;=2^V58.63
 ;;^UTILITY(U,$J,358.3,25038,1,5,0)
 ;;=5^LNG USE ANTIPLTE/THRMBTC
 ;;^UTILITY(U,$J,358.3,25038,2)
 ;;=^329978
 ;;^UTILITY(U,$J,358.3,25039,0)
 ;;=V58.64^^163^1619^22
 ;;^UTILITY(U,$J,358.3,25039,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25039,1,2,0)
 ;;=2^V58.64
 ;;^UTILITY(U,$J,358.3,25039,1,5,0)
 ;;=5^LONG-TERM ANTI-INFLAMTRY
 ;;^UTILITY(U,$J,358.3,25039,2)
 ;;=^329979
 ;;^UTILITY(U,$J,358.3,25040,0)
 ;;=V58.65^^163^1619^25
 ;;^UTILITY(U,$J,358.3,25040,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25040,1,2,0)
 ;;=2^V58.65
 ;;^UTILITY(U,$J,358.3,25040,1,5,0)
 ;;=5^LONG-TERM USE STEROIDS
 ;;^UTILITY(U,$J,358.3,25040,2)
 ;;=^329980
 ;;^UTILITY(U,$J,358.3,25041,0)
 ;;=V58.66^^163^1619^23
 ;;^UTILITY(U,$J,358.3,25041,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25041,1,2,0)
 ;;=2^V58.66
 ;;^UTILITY(U,$J,358.3,25041,1,5,0)
 ;;=5^LONG-TERM USE OF ASPIRIN
 ;;^UTILITY(U,$J,358.3,25041,2)
 ;;=^331584
 ;;^UTILITY(U,$J,358.3,25042,0)
 ;;=V58.67^^163^1619^24
 ;;^UTILITY(U,$J,358.3,25042,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25042,1,2,0)
 ;;=2^V58.67
 ;;^UTILITY(U,$J,358.3,25042,1,5,0)
 ;;=5^LONG-TERM USE OF INSULIN
 ;;^UTILITY(U,$J,358.3,25042,2)
 ;;=^331585
 ;;^UTILITY(U,$J,358.3,25043,0)
 ;;=V58.69^^163^1619^18
 ;;^UTILITY(U,$J,358.3,25043,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25043,1,2,0)
 ;;=2^V58.69
 ;;^UTILITY(U,$J,358.3,25043,1,5,0)
 ;;=5^L/T (CURRENT) USE - OTH MEDS
 ;;^UTILITY(U,$J,358.3,25043,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,25044,0)
 ;;=V65.40^^163^1619^29
 ;;^UTILITY(U,$J,358.3,25044,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25044,1,2,0)
 ;;=2^V65.40
 ;;^UTILITY(U,$J,358.3,25044,1,5,0)
 ;;=5^OTH UNSP COUNSEL NOC
 ;;^UTILITY(U,$J,358.3,25044,2)
 ;;=^87449
 ;;^UTILITY(U,$J,358.3,25045,0)
 ;;=V65.41^^163^1619^9
 ;;^UTILITY(U,$J,358.3,25045,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25045,1,2,0)
 ;;=2^V65.41
 ;;^UTILITY(U,$J,358.3,25045,1,5,0)
 ;;=5^EXERCISE COUNSELING
 ;;^UTILITY(U,$J,358.3,25045,2)
 ;;=^303466
